Malignancy and viability of intraparenchymal brain tumours: correlation between Gd-DTPA contrast MR images and proliferative potentials.
The feasibility of diagnosing the malignancy and viability of intraparenchymal brain tumours using Gd-DTPA, enhanced and unenhanced T1-weighted MRIs was investigated. The relationship between the Gd-DTPA enhancement pattern, the growth fraction (GF) determined by using the anti-bromide-oxyuridine (BrdU) monoclonal antibody, the clinical condition, the proliferative potential and the change of Gd-DTPA enhancement over time was studied. Forty-five patients with intracranial tumours were studied with the static method of Gd-DTPA MRI. The enhanced effect in Gd-DTPA MRIs was dependent on tumour-cell density, vascularization, necrosis, and dilatation of vascular lumen. Tumour-cells were observed in eighty-seven of eighty-nine specimens taken from areas with Gd-DTPA enhanced MRIs. Seventy-four percent of these specimens (64 of 87) showed a malignancy of more than 5% growth fraction. On the other hand, tumour cells were observed in twenty-seven of fifty-six specimens taken from areas with Gd-DTPA unenhanced MRIs. Eighty-five percent of these specimens (23 of 27) showed a malignancy value of less than 5% GF. However, fifteen percent of these specimen showed values between 5 and 15% GF. In the kinetic study of Gd-MRIs five patients who were in a clinically stable condition and one patient who had radionecrosis showed a constant pattern of enhancement or slightly increased enhancement 30 min after injection compared to 4 min after injection. Therefore, GD-DTPA MRI can be used effectively in the diagnosis of tumour viability and malignancy after treatment.
Yoshii
Y
Y
Department of Neurological Surgery, University of Tsukuba, Ibaraki, Japan.
Komatsu
Y
Y
Yamada
T
T
Hyodo
A
A
Nose
T
T
Kobayashi
E
E
D001921:Brain / Q000473:pathology / Q000528:radiation effects; D001932:Brain Neoplasms / Q000175:diagnosis* / Q000473:pathology / Q000556:secondary / Q000601:surgery; D002455:Cell Division / Q000502:physiology*; D002470:Cell Survival / Q000187:drug effects / Q000502:physiology*; D003131:Combined Modality Therapy; D003287:Contrast Media; D016371:Cranial Irradiation; D019786:Gadolinium DTPA; D005910:Glioma / Q000175:diagnosis / Q000473:pathology / Q000601:surgery; D006801:Humans; D008279:Magnetic Resonance Imaging; D015376:Nimustine / Q000008:administration & dosage; D009942:Organometallic Compounds; D004369:Pentetic Acid; D011292:Premedication; D011832:Radiation Injuries / Q000175:diagnosis / Q000473:pathology
D003287:Contrast Media; D009942:Organometallic Compounds; D015376:Nimustine; D004369:Pentetic Acid; D019786:Gadolinium DTPA